Leading Neurotech Researcher Joins NeuroOne Scientific Advisory Board, Guides Further Development of Thin-film Electrodes
Join us in welcoming Vanessa Tolosa, one of the founding members of Neuralink Corp., a company started by Elon Musk to build a complete Brain-Machine Interface, to our Scientific Advisory Board.
Vanessa brings specialized expertise that we believe will help expedite our ongoing development of thin-film electrodes that provide long-term stimulation for treatment of neurological applications, such as epilepsy, Parkinson’s disease, failed back surgery syndrome and other neurological applications that may benefit from high-density thin film electrode technology.
We are pleased to have such a distinguished, highly regarded scientific leader and pioneer as Vanessa on our advisory board.
Vanessa, who has over 10 years of specialized experience developing implantable neural devices, shares our passion in transitioning these technologies from the bench top and bringing them to patients who are in desperate need of these advanced technologies. Her exceptional experience in this field will contribute greatly to NeuroOne’s vision, goals and future direction.
Most recently at Neuralink, she worked to develop a Brain Machine Interface for medical use and other applications. As director of neural interfaces, she directed the design, prototyping, development and testing of technologies related to implantable microelectrodes, electronics micro-assembly and hermetic packaging.
Previously, at Lawrence Livermore National Laboratories (LLNL), Vanessa led all implantable neurotechnology efforts, including high-density electrode technology.
Holder of eight issued patents with five pending applications in this field, she earned a B.S. in Chemical Engineering from the University of Florida and a Ph.D. in Chemical Engineering from the University of California, Los Angeles.
Vanessa believes in our efforts to bring unique thin-film electrodes to the marketplace, and looks forward to helping us refine our implantable neural technology that addresses chronic treatments, as well as making enhancements to our FDA-cleared Evo cortical electrode line.
To learn more about what we do at NeuroOne, click here.